Want to see ABBV full AI Analyst Report?
Revenue by Segment
Breaks down sales across AbbVie’s business lines (e.g., core pharmaceuticals, aesthetics and other segments), revealing how concentrated revenue is in a few top drugs versus diversified streams. Useful for spotting dependence on legacy products, the impact of recent acquisitions like Allergan, and whether new launches are reducing concentration risk.AbbVie's revenue mix has shifted decisively toward immunology and neuroscience—Immunology is the dominant, consistently accelerating cash engine (Skyrizi/Rinvoq outperformance) while neuroscience shows strong double‑digit momentum and upcoming launch upside—supporting management's guidance raise and margin targets. Meanwhile legacy franchises (hematologic oncology) are roughly flat, aesthetics and eye‑care have softened (eye‑care essentially disappears in the latest quarter), and women's health revenue was removed after 2022—amplifying both upside from newer blockbusters and concentration risk if biosimilars/pricing pressure or development setbacks hit.
Date | Other Products | Neuroscience | Immunology | Hematologic Oncology | HCV | Aesthetics | Eye Care | Women's Health |
|---|---|---|---|---|---|---|---|---|
Jun 30, 2026 | $935.00M | $3.23B | $8.79B | $1.65B | $0.00 | $1.28B | $0.00 | $0.00 |
Mar 31, 2026 | $995.00M | $2.88B | $7.29B | $1.63B | $0.00 | $1.19B | $0.00 | $0.00 |
Dec 31, 2025 | $884.00M | $2.96B | $8.63B | $1.66B | $0.00 | $1.29B | $580.00M | $0.00 |
Sep 30, 2025 | $1.01B | $2.84B | $7.88B | $1.68B | $0.00 | $1.19B | $509.00M | $0.00 |
Jun 30, 2025 | $1.04B | $2.68B | $7.63B | $1.68B | $0.00 | $1.28B | $514.00M | $0.00 |
Mar 31, 2025 | $809.00M | $2.28B | $6.26B | $1.63B | $0.00 | $1.10B | $506.00M | $0.00 |
Dec 31, 2024 | $912.00M | $2.51B | $7.29B | $1.69B | $0.00 | $1.30B | $646.00M | $0.00 |
Sep 30, 2024 | $874.00M | $2.36B | $7.05B | $1.69B | $0.00 | $1.24B | $525.00M | $0.00 |
Jun 30, 2024 | $962.00M | $2.16B | $6.97B | $1.63B | $0.00 | $1.39B | $533.00M | $0.00 |
Mar 31, 2024 | $900.00M | $1.97B | $5.37B | $1.54B | $0.00 | $1.25B | $538.00M | $0.00 |